FDA’s Early Breast Cancer pCR Final Guidance Stresses One Trial
Executive Summary
Final guidance from FDA on accelerated approval pathway based on pathological complete response in neoadjuvant breast cancer clarifies that one large trial is the “default” for most applications.
You may also be interested in...
Trial Design Issues, Failure To Follow Guidance Likely to Hurt Merck At Keytruda Advisory Panel
Merck’s decisions to repeatedly ignore US FDA’s advice will be on display as the company tries to convince the agency’s Oncologic Drug’s Advisory Committee the immunotherapy is ready for accelerated approval for patients with high-risk early-stage triple-negative breast cancer based on interim study results.
Neoadjuvant Surrogate Endpoint Is Tough Sell, But FDA Panel Says Perjeta Worth A Chance
Despite concerns about accelerated approval on the basis of pathological complete response, which has not yet been correlated with improvements in longer-term outcomes, FDA panelists say the large body of efficacy and safety data supporting Genentech’s pertuzumab makes it worth the regulatory risk.
Plea To FDA: Set Realistic Bar For New Breast Cancer Trial Endpoint
Commenting on FDA’s draft guidance for accelerated approval using a relatively new surrogate marker of pathologic complete response, Roche/Genentech is wary that FDA may expect too high a bar for results. BIO asks FDA to consider safety when evaluating “magnitude of benefit.”